Background: Ginsenoside Rf is a ginseng saponin found only in Panax ginseng that affects lipid metabolism. It also has neuroprotective and antiinflammatory properties. We previously showed that Korean Red Ginseng (KRG) inhibited the expression of cyclooxygenase-2 (COX-2) by hypoxia via peroxisome proliferatoreactivated receptor gamma (PPARg). The aim of the current study was to evaluate the possibility of ginsenoside Rf as an active ingredient of KRG in the inhibition of hypoxia-induced COX-2 via PPARg. Methods: The effects of ginsenoside Rf on the upregulation of COX-2 by hypoxia and its antimigration effects were evaluated in A549 cells. Docking of ginsenoside Rf was performed with the PPARg structure using Surflex-Dock in Sybyl-X 2.1.1. Results: PPARg protein levels and peroxisome proliferator response element promoter activities were promoted by ginsenoside Rf. Inhibition of COX-2 expression by ginsenoside Rf was blocked by the PPARgspecific inhibitor, T0070907. The PPARg inhibitor also blocked the ability of ginsenoside Rf to suppress cell migration under hypoxia. The docking simulation results indicate that ginsenoside Rf binds to the active site of PPARg.
Introduction
The Panax genus of the Araliaceae family, commonly known as ginseng, is a representative medicinal herb in Asian countries that has been used for more than 2,000 years. Its recent use is not limited to Asia but has been extended to the market of Western countries and is estimated to be worth $2,084 million including ginseng root and its processed products [1] . The global popularity of ginseng consumption indirectly supports the efficacy of ginseng and has scientifically proven its pharmacology [1, 2] . In particular, ginseng reduces inflammation, and both in vitro and in vivo studies have shown that ginseng has antiinflammatory and anticancer effects [3e7] .
Saponins, known as ginsenosides, are widely regarded as the most highly bioactive compounds in ginseng [8] . Single or crude mixtures of saponins have been considered to be responsible for most of the pharmacological effects of ginseng over the years [9] . Based on their chemical structure, ginsenosides are divided into two groups: protopanaxatriol and protopanaxadiol. The protopanaxatriol group includes ginsenosides Rg1, Re, Rf, Rh1, and Rg2.
Ginsenoside Rf is a steroid-like compound linked to sugars. The content of ginsenoside Rf was 0.54 AE 0.26 mg/g (Rg1 contains 2.01 AE 0.65 mg/g) in fresh ginseng and 0.78 AE 0.25 mg/g (Rg1 contains 3.34 AE 0.98 mg/g) in red ginseng [10] . The content of ginsenoside Rf in Panax ginseng is shown as follows: roots, 1.8 AE 0.1 mg/g; stems and leaves, 0.3 AE 0.1 mg/g; and fruits, 3.6 AE 1.1 mg/g [11] . Ginsenoside Rf is a ginseng saponin that is only present in Panax ginseng [1] . Although the concentration of ginsenoside Rf is low, it is an important regulator of lipid metabolism with additional neuroprotective, antinociceptive, and antiinflammatory properties [12e15] .
Hypoxia refers to an overall reduction in tissue oxygen, a characteristic of solid tumors, and causes cell metastasis and invasion [16] . The production of cyclooxygenase-2 (COX-2) is increased by diverse factors, such as hypertonicity, lipopolysaccharide, cytokines, and hypoxia [17e20]. The upregulation of COX-2 increases the risk of metastasis of cancer cells, and the suppression of COX-2 decreases tumor formation and metastasis [21, 22] . Mammary epithelial cells contain peroxisome proliferatoreactivated receptor gamma (PPARg), which is important for the formation of breast tumors and is associated with COX-2 [23] . According to these observations, COX-2 inhibition is important to prevent the invasion of cancer cells induced by hypoxia.
PPARg is a key regulator of adipocytes and is primarily present in adipose tissue. PPARg is also involved in regulating inflammation by controlling COX-2 expression using the PPAR response element within the COX-2 promoter [24e26]. However, the effects of PPARg may vary depending on the cell type, and some studies have indicated that PPARg activates or inhibits COX-2 via PPARg-dependent or -independent mechanisms [27e29].
We reported previously that Korean Red Ginseng (KRG) suppressed COX-2 expression under hypoxia via PPARg [30] . In this study, we aimed to determine whether ginsenoside Rf is the active constituent of KRG leading to the inhibition of hypoxia-induced COX-2 expression via PPARg
Materials and methods

Materials
Ginsenoside Rf was supplied by the Korea Ginseng Cooperation (Daejeon, Korea). 17-b-estradiol, dihydrotestosterone, and bicalutamide were purchased from Sigma (St. Louis, MO, USA). T0070907 was purchased from Selleckchem (Houston, TX, USA). ICI 182,780 (ICI) was purchased from ZENECA pharmaceutical (Tocris, UK). Fetal bovine serum and penicillin/streptomycin were purchased from GIBCO Invitrogen (Grand Island, NY, USA). Cell counting kit-8 (CCK-8) was bought from ENZO (Enzo LifeSciences, Lausen, Switzerland). Anti-COX-2 was used from Cayman Chemical (160106), anti-b-actin was used from Sigma (A5441). Anti-sirtuin-1 (SIRT-1), anti-PPARg, and anti-peroxisome proliferatoreactivated receptor gamma coactivator-1 alpha were used from Santa Cruz Biotechnology (sc-15404, SC-7196, SC-13067).
Cell culture and hypoxic conditions
Maintenance of human lung epithelial A549 and human breast cancer MCF-7 cells as described previously [30] . AR-EcoScreenÔ cells (gift from Dr, Mitsuru Iida, Hiyoshi Corporation, Japan) were derived from a Chinese Hamster Ovary cell line that is stably transformed with a plasmid containing an androgen response element (ARE) fused to a luciferase gene, and a plasmid encoding the androgen receptor (AR) cDNA sequence [31] . AR-EcoScreenÔ cells were maintained in Dulbecco's modified eagle medium/F-12 media containing 10% fetal bovine serum. For the hypoxic condition, A549 cells were incubated at a CO 2 level of 5% with 1% O 2 balanced with N 2 using a hypoxic chamber (Thermo Fisher Scientific, Waltham, MA, USA).
Transfection and luciferase reporter gene assays
A549 cells were seeded at density of 3 Â 10 4 cells/well. After 1-2 days, plasmids were transiently transfected by using polyethylenimine (Polysciences, Warrington, PA, USA). Luciferase reporter gene assay was performed as described previously [30] . Firefly luciferase reporter construct for PPAR response element (PPRE) was kindly provided from Dr. Ron Evans (The Salk Institute, San Diego California, USA). COX-2 firefly luciferase reporter was kindly provided by Dr. Hiroyasu Inoue (Nara Women's University, Nara, Japan). Estrogen response element (ERE)-Luc, a firefly luciferase reporter construct containing the three copies of vitellogenin estrogen response element, was purchased from Addgene (Cambridge, MA, USA, Addgene plasmid number 11354).
Western blot analysis
Western blotting was performed as described previously [30] . The membranes were treated with antibodies against COX-2
(1:1000), b-actin (1:5000), SIRT-1 (1:1000), and PPARg (1:1000).
Cellular migration assays
The migration assay was performed using transwell (8.0 mm pores transwell, Corning, NY, USA) as reported previously [32] . After incubation under normoxia or hypoxia for 24 h, migrated cells were observed and counted using a light microscope.
CCK-8 assays
A549 cells were seeded at a density of 5 Â 10 3 cells/well in a 96-well plate. After 24 h, the indicated chemicals were incubated at normoxia or hypoxia for 24 h. CCK-8 assay was performed as described previously [33] .
Preparation of protein structures
Crystal structure of PPARg (PDB ID: 2ATH) in complex with the agonist BPR1H036 (2-ethanoic acid) was downloaded from RCSB Protein Data Bank [34, 35] . The PPARg structure was optimized for docking as follows: all water molecules were removed from the crystal structure, and the bound ligand was extracted and then prepared with the protein preparation module of the Sybyl-X 2.1.1 (Certara Inc., Princeton, NJ, USA) using default parameters.
Docking with Surflex-Dock
Ginsenoside Rf was docked into the prepared PPARg crystal structure by using Surflex-Dock in Sybyl-X 2.1.1. The program generated the protomol in the active site of PPARg with a threshold of 0.4 and bloat set of 1 around the embedded BPR1H036 molecule. The residues (SER289, HIS323, HIS449, and TYR473) found to interact with BPR1H036 were considered as crucial residues in the active site of PPARg. The main setting was 50 solutions for flexible docking of the ligand, and the other parameters accepted the Surflex-Dock Geom default settings. Docking results were analyzed by using Glide program (Schrödinger LLC, NY, USA).
Statistical analysis
All data were analyzed and expressed as means and standard deviations. The two-tailed, unpaired Student t test was applied using SPSS software (version 23.0; IBM, Armonk, NY, USA).
Results
Ginsenoside Rf induces PPARg transcriptional activity and its protein expression in A549 cells
We previously showed that KRG inhibited hypoxia-induced COX-2 activation via PPARg [32] . In search of the active constituent of KRG that inhibits hypoxia-induced COX-2, ginsenoside Rf was chosen because previous studies suggested that ginsenoside Rf may modulate PPARg [36] . To assess the effects of ginsenoside Rf on hypoxia-induced COX-2 activation, A549 cells were pretreated with ginsenoside Rf for 1 h and exposed to hypoxic conditions for 24 h. Ginsenoside Rf increased the protein levels of SIRT-1 and PPARg compared with hypoxia ( Fig. 1A) . At the same time, 10 mM of ginsenoside Rf efficiently blocked the upregulation of COX-2 transcriptional activity and protein level under hypoxia (Fig. 1A and B) . Next, we wanted to examine whether ginsenoside Rf activated PPARg luciferase reporter activity (Fig. 1C) . Ginsenoside Rf significantly activated PPRE luciferase reporter activity. Ginsenoside Rfe induced PPRE luciferase gene activation was blocked by treatment with the PPARg antagonist, T0070907, indicating that ginsenoside Rf-induced PPRE luciferase gene activation is PPARg-specific. Cell viability was not affected at concentrations of 1e10 mM ginsenoside Rf for 24 h under normoxic or hypoxic conditions (Fig. 1D) .
Ginsenoside Rf inhibits hypoxia-induced COX-2 protein expression and COX-2 transcriptional activity through PPARg in A549 cells
To determine whether PPRE activation is related to COX-2 inhibition by ginsenoside Rf, COX-2 protein levels were measured using T0070907 (Fig. 2A) . The suppression of hypoxia-induced COX-2 protein expression by ginsenoside Rf was blocked by T0070907, indicating that the response involves PPARg. To further identify the involvement of PPARg activation, COX-2 promoter activity was measured following treatment with T0070907 (Fig. 2B) . These results suggest that the suppression of hypoxia-stimulated COX-2 by ginsenoside Rf in A549 cells is dependent on PPARg.
Ginsenoside Rf repress hypoxia-induced cellular migration in A549 cells
To confirm whether ginsenoside Rf inhibits cellular migration via PPARg, migration capability was examined using T0070907 in A549 cells. As shown in T0070907. These results suggest that ginsenoside Rf inhibits hypoxia-induced cellular migration via PPARg.
Ginsenoside Rf has no estrogen receptor or AR transcriptional activity
To determine whether ginsenoside Rf induces other nuclear hormone receptors, estrogen receptor (ER) and AR transcriptional activities were examined. As shown in Fig. 4A, 17 -b-estradiol , as a positive control, induced ERE-transcriptional activity at a concentration of 10 nM in MCF-7 cells. However, ginsenoside Rf did not induce ER transcriptional activity. We also analyzed the anti-ERE transcriptional activity of ginsenoside Rf (Fig. 4B) . Ginsenoside Rf did not exhibit anti-ER transcriptional activity. Moreover, ginsenoside Rf was examined for ARE transcriptional activity (Fig. 4C) . Ginsenoside Rf did not show AR transcriptional activity. Lastly, we A B checked for anti-ARE transcriptional activity of ginsenoside Rf (Fig. 4D) . Ginsenoside Rf did not exhibit anti-AR transcriptional activity. These results suggest that ginsenoside Rf specifically activates PPARg, not ER or AR.
Docking modeling: ginsenoside Rf fits into the agonist binding site of PPARg
To investigate whether ginsenoside Rf directly interacts with PPARg, a molecular docking simulation of the interaction between ginsenoside Rf and PPARg was performed (Fig. 5) . For comparison, the binding pose of ginsenoside Rf was superimposed over the Xray pose of BPR1H036, a known indole-based PPARg agonist (Fig. 5B) . The overall binding mode of ginsenoside Rf predicted by Surflex-Dock was similar to that of BPR1H036. In the X-ray structure, the carboxylate group in the polar head of BPR1H036 formed a hydrogen bond network with key residues of PPARg, including SER289, HIS323, HIS449, and TYR473. The glucopyranoside group of ginsenoside Rf also occupied this site, forming two hydrogen bonds with SER289 and HIS449. This hydrogen bond pattern of the acidic polar head group is conserved in most PPARg agonists, which is believed to be essential for the activity of the ligand. Moreover, the tetracyclic skeleton of ginsenoside Rf exhibited strong hydrophobic interactions with PPARg, playing an important role in the binding of ginsenoside Rf to the protein. These results indicate that ginsenoside Rf may directly interact with PPARg; however, further studies are required to confirm the binding mode of ginsenoside Rf to PPARg.
Discussion
Many studies have shown that KRG has antioxidant and antiinflammatory effects both in vitro and in vivo [37, 38] . We previously demonstrated that KRG inhibits hypoxia-induced COX-2 activation . All experiments were repeated at least three times. * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, p > 0.05 is indicated by "n.s." for not significant. AR, androgen receptor; CDX, bicalutamide; ERE, estrogen response element; SD, standard deviation.
via PPARg [30] . In search of the active constituent of KRG that inhibits hypoxia-induced COX-2, we found that ginsenoside Rf activates PPARg and suppresses hypoxia-induced COX-2 via PPARg. PPARg is a member of the nuclear receptor superfamily and is a ligand-dependent transcription factor [39] . PPARg regulates glucose metabolism, fatty acid storage, and adipocyte differentiation and is a target of antidiabetic drugs [40, 41] . Several studies have shown that the ginsenosides Rg3 and Rh2 and compound K inhibit adipogenesis via the regulation of PPARg and CCAAT/enhaancer-binding protein alpha expression in 3T3-L1 cells, human primary preadipocytes, and mice [42] . Indeed, it has been suggested that ginsenoside Rf binds directly to the active site of PPARg [36] . However, these ginsenosides downregulate PPARg and perilipin protein expression in 3T3-L1 cells, indicating an antiadipogenic effect [42] . It was recently recognized that PPARg plays a fundamental role in the immune response through its ability to inhibit the expression of inflammatory cytokines and induce the differentiation of immune cells against antiinflammatory phenotypes [24] . Hesperetin, a flavanone from the fruit peel of Citrus aurantium L, exhibits strong antiinflammatory effects through the upregulation of PPARg [43] . Moreover, fenretinide, a synthetic ligand of PPARg, induces antiinflammatory activity, although its exact mechanism is not fully understood [44] . Our data are consistent with previous results demonstrating that ginsenoside Rf modulates PPARg and appears to have distinct functions, such as antiadipogenesis and antiinflammation, according to the cell type. In our study, ginsenoside Rf specifically inhibited COX-2 expression via PPARg activation under hypoxic conditions. The COX-2 suppression we observed may be because of the sum of the activities of each component and their interactions, as ginsenosides Rb1 and Rg1 elicited some response, albeit weaker than that of ginsenoside Rf. Moreover, the inhibition of COX-2 expression and cellular migration under hypoxia were dependent on PPARg activation. The docking simulation results indicated that ginsenoside Rf binds to the active site of PPARg; however, further studies are required to confirm the binding mode. These findings provide a mechanical explanation for the effects of ginsenoside Rf on metabolic disorders and cancer.
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